Our Pricing

Wegovy Pen Doses: Clinical Trial Weight Loss Results

Published on: June 03, 2026

Understanding wegovy pen doses clinical trial results uk is essential before starting treatment. Each Wegovy pen contains semaglutide at precisely measured doses, and clinical trials demonstrate significant weight loss outcomes when used alongside lifestyle modifications. At Cured Pharmacy, we provide genuine UK-licensed Wegovy from £79.00 with transparent pricing and free clinical consultation by UK prescribers.

How Many Doses Are in Each Wegovy Pen?

Each Wegovy pen is a single-dose, pre-filled injection device designed for once-weekly subcutaneous administration. Unlike multi-dose pens used for other medications, every Wegovy pen contains exactly one dose at a specific strength, ranging from 0.25mg to 2.4mg [1].

The treatment follows a structured dose escalation schedule over 16 weeks, starting at 0.25mg and gradually increasing to the maintenance dose of 2.4mg weekly. This gradual titration minimises gastrointestinal side effects whilst allowing your body to adapt to semaglutide's effects on appetite regulation [1].

Patients receive four pens per prescription box, providing one month of treatment at each dose level. This packaging ensures you always have the correct strength for your current stage in the dosing schedule, as determined by your UK prescriber during clinical assessment.

STEP Clinical Trial Weight Loss Results

The STEP (Semaglutide Treatment Effect in People with obesity) programme represents the largest clinical evidence base for Wegovy. In the pivotal STEP 1 trial, participants achieved an average 15.3% body weight reduction over 68 weeks when using the 2.4mg maintenance dose alongside lifestyle interventions [2].

Nearly one-third of participants lost 20% or more of their initial body weight — a threshold rarely achieved with previous pharmacological treatments [2]. These results significantly exceeded the 2.6% average weight loss observed in the placebo group, demonstrating semaglutide's clear clinical efficacy.

The STEP 5 trial extended follow-up to 104 weeks, showing sustained weight loss of 15.2% at two years, confirming that Wegovy delivers durable outcomes when treatment continues [3]. Weight loss plateaued around week 60, with maintenance thereafter, indicating the importance of ongoing therapy rather than short-term use.

Real-World Effectiveness vs Clinical Trials

Whilst clinical trials provide controlled evidence, real-world outcomes can vary based on adherence, lifestyle factors, and individual metabolic response. UK observational studies suggest that patients who maintain weekly injections and implement dietary changes achieve results comparable to trial populations, though some discontinue treatment due to side effects or cost considerations.

Wegovy Dosing Schedule Explained

The Wegovy dose escalation follows a fixed 16-week titration protocol: 0.25mg weekly for 4 weeks, then 0.5mg for 4 weeks, 1mg for 4 weeks, 1.7mg for 4 weeks, and finally 2.4mg as the maintenance dose [1]. This gradual increase is clinically designed to reduce nausea and other gastrointestinal symptoms.

If you experience persistent side effects at any dose level, your UK prescriber may recommend staying at your current dose for an additional 4 weeks before escalating. Some patients remain on 1.7mg long-term if they cannot tolerate the 2.4mg dose, though clinical trial data primarily reflects outcomes at the full maintenance dose [1].

Missing doses requires careful management — if you miss a dose and it has been less than 5 days, take it as soon as possible. If more than 5 days have passed, skip the missed dose and resume your regular schedule. Prolonged treatment interruptions may require restarting the titration schedule under prescriber guidance.

Maintenance Phase Duration

Once you reach 2.4mg weekly, this becomes your ongoing maintenance dose for as long as treatment continues and remains clinically appropriate. The STEP trials demonstrate that stopping Wegovy typically results in weight regain, suggesting that many patients require long-term therapy to maintain weight loss outcomes [3].

Comparing Wegovy to Other Weight Loss Treatments

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone regulating appetite and glucose metabolism. It differs from dual-pathway treatments and older weight loss medications in both mechanism and clinical outcomes observed in trials.

Semaglutide-based treatments have demonstrated superior weight loss compared to earlier injectable options in head-to-head trials, though newer dual GIP/GLP-1 receptor agonists show even greater average reductions in some studies [4]. Your UK prescriber will assess which treatment aligns with your medical history, weight loss goals, and tolerability profile.

Oral medications remain available for patients who prefer non-injectable options, though clinical trial data generally shows more modest weight loss outcomes. The choice between treatments depends on individual circumstances, contraindications, and prescriber clinical judgement following your online assessment.

Side Effects and Safety Profile from Clinical Trials

In the STEP trials, the most common side effects were gastrointestinal: nausea (44%), diarrhoea (30%), vomiting (24%), and constipation (24%) [2]. These symptoms typically occurred during dose escalation and decreased in intensity over time as patients adapted to treatment.

Serious adverse events were rare but included pancreatitis, gallbladder disease, and hypoglycaemia in patients using concurrent diabetes medications. The gradual dosing schedule is specifically designed to minimise side effect severity whilst maintaining therapeutic efficacy [1][2].

Wegovy is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Your UK prescriber will review your complete medical history during clinical assessment to ensure Wegovy is safe and appropriate for you.

Managing Common Side Effects

Most gastrointestinal symptoms can be managed through dietary modifications: eating smaller portions, avoiding high-fat foods, and staying well-hydrated. If side effects persist or worsen, contact your prescriber — dose adjustments or temporary treatment pauses may be recommended rather than discontinuation.

Starting Wegovy at Cured Pharmacy

At Cured Pharmacy, Wegovy is available from £79.00, with transparent pricing displayed before your free online consultation. Our UK-registered clinical team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), reviews every assessment to ensure safe, appropriate prescribing aligned with MHRA guidance.

Your consultation takes under 3 minutes and covers medical history, current medications, weight loss goals, and contraindications. If Wegovy is clinically suitable, your prescription is dispensed from our UK pharmacy and delivered in 100% discreet packaging directly to your address.

All Wegovy supplied through Cured Pharmacy is genuine UK-licensed medication sourced through regulated channels. We never supply unlicensed or imported products. Your treatment includes ongoing prescriber support — contact us anytime if you experience side effects or have questions about your dosing schedule.

Scientific References

1. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
4. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.